OncoSil Medical Ltd (AU:OSL)
ASX:OSL
Top Page
OncoSil Medical Ltd
(Sydney:OSL)
Select Model
Select Model
Rating:39Underperform
Price Target:
AU$0.45
â–¼(-53.71% Downside)
Action:DowngradedDate:03/20/26
The score is driven primarily by weak financial health (ongoing losses and negative cash flows) and bearish technicals (price below all key moving averages with negative MACD and very low RSI/Stoch). Valuation contributes little support due to a negative P/E and no dividend yield data.
Positive Factors
Niche product and clinical focus
OncoSil's device targets locally advanced pancreatic cancer with EUS-guided brachytherapy as an adjunct to chemotherapy. That focused clinical niche addresses a high unmet need, supporting durable physician adoption, clear go-to-market positioning and long-term demand if clinical outcomes remain favorable.
Negative Factors
Persistent unprofitability
Deeply negative gross, net, EBIT and EBITDA margins demonstrate the business currently does not generate operational profits. Persistent unprofitability will erode equity, limit reinvestment capacity and require sustained improvements in pricing, cost structure, or scale to achieve durable viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Niche product and clinical focus
OncoSil's device targets locally advanced pancreatic cancer with EUS-guided brachytherapy as an adjunct to chemotherapy. That focused clinical niche addresses a high unmet need, supporting durable physician adoption, clear go-to-market positioning and long-term demand if clinical outcomes remain favorable.
Read all positive factors
OncoSil Medical Ltd (OSL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$15.50M
Dividend YieldN/A
Average Volume (3M)24.03K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth126.62%
EPS Growth33.53%
CountryAU
Employees2
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.24
Shares Outstanding30,697,231
10 Day Avg. Volume8,764
30 Day Avg. Volume24,029
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.23
Price to Sales (P/S)11.20
P/FCF Ratio-1.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OncoSil Medical Ltd Business Overview & Revenue Model
Company Description
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachythe...
How the Company Makes Money
null...
OncoSil Medical Ltd Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.33M | 1.17M | 516.63K | 367.68K | 231.79K | 213.07K |
| Gross Profit | -3.94M | -1.08M | -993.00K | -1.22M | -6.73M | -748.00K |
| EBITDA | -15.34M | -15.06M | -12.91M | -11.17M | -11.41M | -11.31M |
| Net Income | -12.92M | -15.10M | -11.91M | -11.34M | -10.73M | -10.43M |
Balance Sheet | ||||||
| Total Assets | 7.13M | 7.15M | 6.72M | 11.47M | 13.07M | 14.15M |
| Cash, Cash Equivalents and Short-Term Investments | 2.85M | 5.11M | 4.50M | 9.39M | 11.28M | 12.24M |
| Total Debt | 42.47K | 69.92K | 70.67K | 170.81K | 304.21K | 484.37K |
| Total Liabilities | 3.29M | 4.04M | 1.98M | 1.59M | 1.91M | 2.45M |
| Stockholders Equity | 3.84M | 3.10M | 4.74M | 9.88M | 11.16M | 11.70M |
Cash Flow | ||||||
| Free Cash Flow | -12.91M | -12.08M | -11.02M | -11.37M | -10.12M | -8.87M |
| Operating Cash Flow | -12.91M | -12.06M | -10.82M | -11.32M | -10.11M | -8.82M |
| Investing Cash Flow | -6.56K | -14.96K | -197.06K | -57.82K | -5.83K | -54.00K |
| Financing Cash Flow | 7.35M | 12.73M | 6.13M | 9.49M | 9.16M | 111.25K |
OncoSil Medical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$3.61B | -3.16 | -890.76% | ― | 55.91% | 22.60% | |
48 Neutral | AU$24.72M | -1.40 | -98.14% | ― | 14.84% | 39.64% | |
44 Neutral | AU$98.45M | -6.27 | -54.48% | ― | 34.20% | -23.90% | |
44 Neutral | AU$144.05M | -10.00 | -70.29% | ― | ― | -257.32% | |
41 Neutral | AU$41.39M | -2.66 | -180.06% | ― | -14.25% | -22.83% | |
39 Underperform | AU$15.50M | -1.00 | -372.27% | ― | 126.62% | 33.53% |
* Healthcare Sector Average
AU:OSL
OncoSil Medical Ltd
0.51
-0.44
-46.50%
AU:CYC
Cyclopharm Limited
0.82
-0.31
-27.88%
AU:MX1
Micro-X Ltd.
0.06
>-0.01
-5.00%
AU:EMV
EMvision Medical Devices Ltd.
1.55
-0.25
-13.89%
AU:CBL
Control Bionics Ltd.
0.06
0.02
36.36%
AU:4DX
4DMedical Ltd
6.13
5.88
2352.00%
OncoSil Medical Ltd Corporate Events
OncoSil Updates Market on Change in Substantial Shareholder Interests
Mar 19, 2026
OncoSil Medical Ltd has lodged a notice of change of interests of a substantial holder under Australia’s Corporations Act, indicating an update to a major shareholder’s voting power in the company. The filing, signed by Chief Operating...
OncoSil Director Increases Indirect Stake via Capital Raising
Mar 19, 2026
OncoSil Medical has disclosed a change in director Thomas Duthy’s indirect holdings following his participation in a recent capital raising. Through CIPA Investments Pty Ltd, Duthy acquired 50,537 new shares at $0.68 each, along with 50,537 ...
OncoSil Flags Isolated Administrative Lapse in Director Interest Disclosure
Mar 19, 2026
OncoSil Medical has disclosed a late lodgement of an Appendix 3Y relating to CEO and managing director Nigel Lange, reflecting the lapse and cancellation of certain performance rights and employee loan-funded shares in line with their terms. The c...
OncoSil Medical Securities Reinstated to ASX Quotation
Mar 17, 2026
OncoSil Medical has had its OSLOE class securities reinstated to quotation on the Australian Securities Exchange following confirmation of compliance with ASX Listing Rule 2.5. The resumption of trading restores liquidity and market access for hol...
OncoSil Raises Institutional Capital via Share Placement and Issues Cleansing Notice
Mar 17, 2026
OncoSil Medical has raised new equity by issuing 4,100,470 fully paid ordinary shares at $0.68 each to sophisticated and institutional investors via a placement, providing additional capital to support its interventional oncology business. The sha...
OncoSil Options Register Shows High Concentration Among Institutional Holders
Mar 17, 2026
OncoSil Medical Ltd has disclosed the top 20 holders of its listed options, exercisable at $0.90 and expiring on 30 June 2027, which collectively control 86.28% of the 12,082,126 options on issue. The largest positions are held by institutional no...
OncoSil Medical Seeks ASX Quotation for New Shares and Options
Mar 17, 2026
OncoSil Medical Ltd has applied for quotation on the ASX of 2,951,918 new fully paid ordinary shares and an equal number of deferred options expiring on 30 June 2027. The new securities, issued on 17 March 2026 and linked to a previously announced...
OncoSil seeks ASX quotation for small new share issue
Mar 17, 2026
OncoSil Medical Ltd has applied for quotation on the ASX of 29,509 new ordinary fully paid shares, to be issued on March 17, 2026. The securities are being quoted as part of previously announced transactions, indicating only a minor increase in th...
OncoSil Seeks ASX Quotation for New Tranche of Deferred Options
Mar 17, 2026
OncoSil Medical Ltd has lodged an application with the ASX for quotation of 306,678 deferred options, designated as OSLOE and expiring on June 30, 2027, with an issue date of March 17, 2026. The options are being quoted as securities issued under ...
OncoSil Medical Seeks ASX Quotation for New Shares and Options
Mar 17, 2026
OncoSil Medical has applied to the ASX for quotation of 4,100,470 new ordinary fully paid shares and 8,823,530 deferred options expiring on 30 June 2027. The securities, issued on 17 March 2026 as part of previously announced transactions, expand ...
OncoSil Raises $2m in Fully Subscribed Entitlement Offer to Fund Cancer Device Expansion
Mar 16, 2026
OncoSil Medical has completed a fully subscribed non-renounceable entitlement offer, raising about $2 million including the underwritten portion, to support clinical trials, manufacturing, sales and marketing, market access initiatives and working...
OncoSil shareholders back capital and remuneration resolutions at EGM
Mar 12, 2026
OncoSil Medical Ltd, an interventional oncology specialist focused on device-based treatments for advanced pancreatic cancer, has developed its OncoSil device to deliver targeted radiotherapy via Phosphorous-32 microparticles, and holds marketing ...
ASX Suspends Trading in Specific OncoSil Security Class
Mar 10, 2026
The Australian Securities Exchange has suspended quotation of a specific class of OncoSil Medical Ltd securities, identified by the code OSLOE, under Listing Rule 17.3.4 pending the company’s compliance with Listing Rule 2.5. The suspension ...
OncoSil Medical Opens Entitlement Offer as It Seeks Shareholder Approval for Capital Raising
Feb 11, 2026
OncoSil Medical has opened its entitlement offer to eligible shareholders, confirming that the prospectus and personalised entitlement and acceptance forms have been dispatched and that applications will be accepted until 5:00 p.m. AEDT on 10 Marc...
OncoSil seeks ASX quotation for 4.7m new shares
Feb 9, 2026
OncoSil Medical Ltd has applied for quotation on the ASX of 4,723,060 additional ordinary fully paid shares, with an issue date of 9 February 2026. The new securities arise from transactions previously notified to the market, modestly expanding th...
OncoSil Raises Capital via Institutional Placement and Issues Cleansing Notice
Feb 9, 2026
OncoSil Medical has raised new equity by issuing 4,723,060 fully paid ordinary shares at A$0.68 each to sophisticated and institutional investors via an institutional placement. The company stated that the shares were issued without a prospectus u...
OncoSil consolidates company secretary role after David Wood exit
Feb 4, 2026
OncoSil Medical announced the resignation of joint company secretary David Wood, leaving Tim Luscombe as the sole company secretary responsible for ASX communications, underscoring continuity in the company’s governance framework amid its on...
OncoSil Updates Terms and Timetable of Pro Rata Securities Offer
Feb 3, 2026
OncoSil Medical Ltd has updated details of its proposed non-renounceable pro rata issue of securities, lodging an amended Appendix 3B with the ASX. The company has revised the timetable for the offer, pushing back a key date from 12 March 2025 to ...
OncoSil Medical Plans Equity Placement of Up to 4.7 Million Shares
Feb 3, 2026
OncoSil Medical Ltd has announced a proposed issue of up to 4,723,060 new fully paid ordinary shares under a placement or similar capital-raising mechanism, with an intended issue date of 9 February 2026. The additional securities, to be quoted on...
OncoSil Launches Fully Underwritten $2m Entitlement Offer
Feb 3, 2026
OncoSil Medical Ltd has released a prospectus for a fully underwritten, non-renounceable pro-rata entitlement offer to raise up to approximately $2 million before costs, issuing one new share for every 6.4 shares held at $0.68 per share, with one ...
OncoSil Raises $8m to Fund German Trial and European Expansion
Feb 3, 2026
OncoSil Medical has secured firm commitments for an $8 million capital raising, comprising a $6 million two-tranche placement to institutional and professional investors and a fully underwritten $2 million non-renounceable entitlement offer, both ...
OncoSil posts striking 83% surgical resection rate in early Turkish pancreatic cancer use
Jan 30, 2026
OncoSil Medical reported strong early real-world clinical outcomes from Ankara Bilkent City Hospital in Türkiye, where six patients with unresectable locally advanced pancreatic cancer were treated with the OncoSil™ device alongside sta...
OncoSil Posts Record Q2 Dose Sales as European Rollout and Clinical Data Gain Momentum
Jan 30, 2026
OncoSil Medical reported a pivotal second quarter of FY26, delivering record dose sales, with unit volumes up 60% and revenue rising 70% year-on-year, underscoring accelerating clinical adoption and strengthening market presence. The company compl...
OncoSil Requests ASX Trading Halt Ahead of Capital Raising Announcement
Jan 30, 2026
OncoSil Medical Ltd has requested an immediate trading halt in its securities on the ASX as it prepares to announce a capital raising. The halt will remain in place until the company releases details of the capital raising or until the start of no...
OncoSil Hits Key Milestone in TRIPP-FFX Pancreatic Cancer Trial, Eyes Label Expansion
Jan 28, 2026
OncoSil Medical has completed the Last Patient, Last Visit milestone in its TRIPP-FFX clinical trial, a prospective multi-centre study assessing the safety and efficacy of the OncoSil™ device when used alongside FOLFIRINOX chemotherapy in pa...
OncoSil Marks First Treatment at Major Berlin Hospital as German Expansion Gathers Pace
Jan 27, 2026
OncoSil Medical has announced the first successful OncoSil™ treatment at Vivantes Neukölln Hospital in Berlin, one of the largest hospitals in Germany and a leading centre for gastrointestinal oncology within the country’s largest...
OncoSil Marks First Pancreatic Cancer Treatment at Acibadem Maslak in Turkish Expansion Push
Jan 15, 2026
OncoSil Medical has completed the first treatment using its OncoSil™ device at Acibadem Maslak Hospital in Istanbul, marking a key milestone in its international expansion strategy. Türkiye, with around 8,500 new pancreatic cancer cases...
OncoSil Study Shows Survival and Surgical Gains in Advanced Pancreatic Cancer
Jan 12, 2026
OncoSil Medical announced that a peer‑reviewed study in Gastrointestinal Endoscopy found that patients with locally advanced pancreatic cancer treated with the OncoSil™ phosphorus‑32 implant plus chemotherapy experienced better o...
OncoSil Medical Secures A$1.84m R&D Tax Refund to Support Pancreatic Cancer Device Expansion
Jan 7, 2026
OncoSil Medical has received a A$1.84 million refund under Australia’s RD Tax Incentive program for eligible research and development activities conducted in the 2025 financial year, reinforcing government-backed support for its ongoing inno...
OncoSil Medical Announces Lapse of 7,500 Conditional Options
Jan 6, 2026
OncoSil Medical Ltd, an ASX-listed oncology-focused medical company, develops and commercialises cancer treatment technologies and related medical devices.The company has notified the cessation of 7,500 OSLAR options, which were due to expire in N...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.